I’m no expert on how clinical trials work from a patient perspective. But after reading Rock_Robster, you know, the guy in the Imugene trial, of having to submit to a very uncomfortable SPECT scan, it made be wonder whether we ought to be really thinking about the patient perspective first. How do patients feel? I wonder if they read these threads. “OK buster, it’s time for you to submit to another scan to satisfy the investors”. No. The data cuts will come when everyone is good and ready -patients, clinicians analysts… the lot.
https://coloncancersupport.colonclub.com/viewtopic.php?t=66973
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.001(9.09%) |
Mkt cap ! $89.60M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $524.0K | 42.71M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 7992137 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 5317164 | 34 |
View Market Depth
| Last trade - 13.43pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |